Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
about
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia.Advances in the role of cytogenetic analysis in the molecular diagnosis of B-cell lymphomas.From identification of the BTK kinase to effective management of leukemia.Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.How I manage ibrutinib-refractory chronic lymphocytic leukemia.Evolutionary scalpels for dissecting tumor ecosystems.Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia.Chronic lymphocytic leukaemia genomics and the precision medicine era.Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas.Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.Dynamic changes in clonal cytogenetic architecture during progression of chronic lymphocytic leukemia in patients and patient-derived murine xenografts.Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.The Phospholipase Cγ2 Mutants R665W and L845F Identified in Ibrutinib-resistant Chronic Lymphocytic Leukemia Patients Are Hypersensitive to the Rho GTPase Rac2 Protein.Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia.Recent therapeutic advances in chronic lymphocytic leukemia.High-dimension single-cell analysis applied to cancer.The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Terminating B cell receptor signaling.Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.Imprecision and DNA Break Repair Biased Towards Incompatible End Joining in Leukemia.Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.Clonal evolution in leukemia.Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.SnapShot: Chronic Lymphocytic Leukemia.Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.
P2860
Q30252869-415AE97C-203A-4F66-8D84-CE3161D20C1AQ38685006-0D956E9D-C930-4100-9370-3C65ABF5C325Q38719429-A4843EB2-B715-40D9-A953-20B2C67154AFQ38744632-34417CB6-FF59-4D51-ABF9-4E7C76B555C1Q38798801-928FEA49-0734-41F7-BB3F-D94868A13A82Q38817591-ACCAA675-E22B-4EFF-BCF3-E9B28F4C3F76Q38818283-92520DCD-94EA-4AB4-992B-9CEC1629924BQ38974011-9131999D-CBD4-4262-821F-1BA0852905EDQ39010883-E36FF536-D7E9-4347-87AF-4483558760C4Q39016282-7874C46F-14C9-4905-88CF-3915ABF153E2Q39030938-29F77938-627A-49EA-8DF8-43C7045C796EQ39169789-0BCBA748-DEF4-404B-87EC-218049697CDFQ39263974-FEB496CD-9001-4288-B45D-371E48A4372DQ39325783-D5576A6E-FD3D-4EF3-AE5F-EADD34E67966Q39432317-00ED5310-D911-4A2A-A27D-36C4A072F221Q40397638-0CA167B7-8663-484E-A20F-A295EB91EBDDQ41280348-347D1688-CF28-4316-A586-3F6EFAC185F2Q42378526-5D813226-ABF6-4AEB-983C-A9B6FA5167EDQ42383180-76BC7C42-93E2-4018-901A-976940461DC6Q44225251-D7D87089-490A-4304-8889-E83EA58E7CC6Q46318389-B1DB0073-1A98-4FC0-B13A-0670F9C95EA3Q46318813-C7B6B8B0-6B8D-4D8A-B2B1-DD0BDF56D165Q47102996-562F8FA9-C334-44BE-A700-B741D78DEB20Q47105054-C604E9D8-E569-47D0-93BE-2F8D58318E4FQ47300370-1D9E7150-6310-4926-8D35-118507FB836FQ47340390-BD98FA77-98CD-478D-8034-DC91EF1B22BDQ47424531-A180EEB7-75B7-4429-BF30-D341813D8004Q47674917-BC35801C-400E-412B-A2CD-357D3D480DE1Q47780043-D6AE03E2-1AFE-48F5-B694-A1797440BCA0Q48298180-216E4FAC-7B05-4D15-B88C-057B37CB6B02Q49557852-F55EDFFE-9822-45A3-8B4A-F14F9D8A2724Q49582344-349917F1-3FC3-4F6F-B675-B03490C318E5Q49789839-9C21688C-2C4C-45DB-8788-A9EB97055A76Q50025593-160374F5-5ABE-45CD-840D-BC93FCB3BAD2Q50072188-19217BD9-8255-4C86-9D8F-9FC5CEA0BEFEQ50074012-CE41B878-2460-4A62-B3D6-7897521E7115Q50110556-E583FB1C-5DE6-4974-BF49-0FCB928A93F0Q50430435-5743C84D-9A76-4F46-B0AE-87E7043C80EAQ51014811-B1FD73BF-8A79-4EAF-A6EE-9E843AA3F8AAQ52645845-E1A18F69-373C-460A-A7C9-8B111B1E07BB
P2860
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Clonal evolution in patients w ...... resistance to BTK inhibition.
@en
type
label
Clonal evolution in patients w ...... resistance to BTK inhibition.
@en
altLabel
Clonal evolution in patients w ...... g resistance to BTK inhibition
@en
prefLabel
Clonal evolution in patients w ...... resistance to BTK inhibition.
@en
P2093
P2860
P50
P356
P1476
Clonal evolution in patients w ...... resistance to BTK inhibition.
@en
P2093
Adrian M Dubuc
Anthony Letai
Cameron Fraser
Catherine J Wu
Chip Stewart
Dan A Landau
David A Weitz
Donna Neuberg
Huidan Zhang
Jan A Burger
P2860
P2888
P356
10.1038/NCOMMS11589
P407
P50
P577
2016-05-20T00:00:00Z
P6179
1036782490